Novexatin(Novexatin) - _专利_临床

概要

基本信息

药物类型

合成多肽

别名

NVXT、NVXT Solution

+ [1]

靶点-

作用机制

细胞膜通透性增强剂

治疗领域

感染皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

甲癣

原研机构

NovaBiotics Ltd.

在研机构-

非在研机构

Taro Pharmaceuticals U.S.A., Inc.

NovaBiotics Ltd.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C42H84N28O7

InChIKeyNVZLKNHDHPPJHL-RMIXPHLWSA-N

CAS号942577-31-3

Sequence Code 6951

关联

2

项与 Novexatin 相关的临床试验

NCT02933879

/ Completed临床2期

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of NVXT topical product in Patients with Mild to Moderate Onychomycosis

开始日期2016-03-21

申办/合作机构

Taro Pharmaceuticals U.S.A., Inc.

NCT02343627

/ Completed临床2期

A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Assess the Safety and Efficacy of NVXT Solution in Patients With Mild-to-Moderate Fungal Infection of the Toe Nail

This study will examine the safety, tolerability and efficacy of NVXT in a new formulation in patients with mild-to-moderate fungal infection of the toe nail.

开始日期2014-12-01

申办/合作机构

Taro Pharmaceuticals U.S.A., Inc.

100 项与 Novexatin 相关的临床结果

登录后查看更多信息

100 项与 Novexatin 相关的转化医学

登录后查看更多信息

100 项与 Novexatin 相关的专利（医药）

登录后查看更多信息

6

项与 Novexatin 相关的文献（医药）

2023-08-02·Medical Mycology

Correction to: NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile

作者: O′Neil, Deborah A. ; Miller, Lorna ; Robertson, Jennifer C. ; Mercer, Derry K. ; Stewart, Colin S.

2022-05-01·Journal of Drugs in Dermatology4区 · 医学

Future Fungal Fighters in Dermatology: Novel Antifungal Drug Pipeline

4区 · 医学

Review

作者: Khalfe, Yasmin ; Rosen, Theodore

Over the last decade, major advances in antifungal drug development have occurred. Novel drugs in the pipeline include ME1111, MAT2203, rezafungin, ibrexafungerp, olorofim, fosmanogepix, MGCD290, VT-1161, NP213, T-2307, aureobasidin A, and nikkomycin Z. While most of these “future fungal fighters” have been developed to address invasive fungal infections (IFI), there is potential for dermatologists to benefit as these drugs may be adapted for superficial infections. Here, we review the major developments in novel antifungals and examine the ways in which dermatologists may gain from these recent innovations. J Drugs Dermatol. 2022;21(5):496-501. doi:10.36849/JDD.6373.

2020-11-10·Medical Mycology3区 · 医学

NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile

3区 · 医学

Article

作者: Mercer, Derry K ; Miller, Lorna ; Stewart, Colin S ; O'Neil, Deborah A ; Robertson, Jennifer C

AbstractNP213 (Novexatin®) is a novel antifungal peptide specifically designed for the topical treatment of onychomycosis. NP213 was designed using host defense peptides (HDP), essential components of the innate immune response to infection, as a template. NP213 is a water-soluble cyclic fungicidal peptide that effectively penetrates human nail. NP213 demonstrated a promising preclinical and clinical safety profile, with no evidence of systemic exposure following topical application to the skin and nails. NP213 was efficacious in two phase IIa human trials with 43.3% of patients having no fungi detectable by culture of fragments from NP213-treated nails after 180 days in the first study and likewise 56.5% of patients were culture negative for dermatophytes after 360 days in the second phase IIa study. In both trials, NP213 was applied daily for only 28 days in marked contrast to other topical onychomycosis treatments that require application for up to 52 weeks. Patient reported outcomes from the phase IIa studies were positive with participants recording an improved appearance of their nails after only 14 days of application. All fungi identified in these studies were Trichophyton spp. NP213 (Novexatin®) is a promising, highly differentiated peptide-based candidate for the topical treatment of onychomycosis, addressing the infectious cause and cosmetic issues of this very common condition.

1

项与 Novexatin 相关的新闻（医药）

2015-09-10

·BioPortfolio

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015

Recently added to the BioPortfolio report store, Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015 is a new report from Global Markets Direct published on 2015-07-30. This 68-page report is available in PDF from $2000. Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015’, provides an overview of the Onychomycosis (Tinea Unguium)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage … Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Onychomycosis (Tinea Unguium) Overview 8 Therapeutics Development 9 Pipeline Products for Onychomycosis (Tinea Unguium) - Overview 9 Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis 10 Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies 11 Onychomycosis (Tinea Unguium) - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Onychomycosis (Tinea Unguium) - Products under Development by Companies 15 Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development 16 Anacor Pharmaceuticals, Inc. 16 Eisai Co., Ltd. 17 Helix BioMedix, Inc. 18 Hexima Limited 19 Meiji Seika Pharma Co., Ltd. 20 Moberg Pharma AB 21 NAL Pharmaceuticals Ltd. 22 Nihon Nohyaku Co., Ltd. 23 Novabiotics Limited 24 Nuvo Research Inc. 25 Viamet Pharmaceuticals, Inc. 26 Onychomycosis (Tinea Unguium) - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 AN-2718 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 E-1224 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ELS-160 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 HB-1275 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 HXP-124 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 luliconazole - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ME-1111 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 NAL-3216 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 NP-213 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 terbinafine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 terbinafine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 VT-1161 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Onychomycosis (Tinea Unguium) - Recent Pipeline Updates 53 Onychomycosis (Tinea Unguium) - Dormant Projects 58 Onychomycosis (Tinea Unguium) - Discontinued Products 61 Onychomycosis (Tinea Unguium) - Product Development Milestones 62 Featured News & Press Releases 62 Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical… For more information open Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015. SKU: GMDHC6868IDB

First in Class

100 项与 Novexatin 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
甲癣	临床前	英国	NovaBiotics Ltd.	2009-09-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02343627 (Pubmed \| Med Mycol) 人工标引	临床2期	甲癣	-	NP213	憲壓鏇範鏇獵醖願膚築(獵簾齋窪襯鏇鑰簾餘範) = 網衊膚遞鏇構鏇糧壓窪壓膚蓋餘憲觸糧範網繭 (鹽艱獵簾製憲憲鹹膚製 ) 更多	积极	2020-11-10
NCT02933879 (CTgov)	临床2期	甲癣	184	NVXT (NVXT Topical Treatment Group A)	鬱積構鏇餘網餘築衊憲(鬱觸憲淵廠願築艱選糧) = 衊積淵觸廠憲鬱齋襯蓋膚繭蓋淵鹽繭簾願範窪 (衊遞鹽淵觸膚願膚襯衊, 願齋願製網襯憲鏇願遞 ~ 顧夢壓顧鑰廠糧廠壓艱) 更多	-	2018-12-20
				NVXT (NVXT Topical Treatment Group B)	鬱積構鏇餘網餘築衊憲(鬱觸憲淵廠願築艱選糧) = 壓醖築遞艱積艱繭壓糧膚繭蓋淵鹽繭簾願範窪 (衊遞鹽淵觸膚願膚襯衊, 膚簾襯糧簾夢繭鬱遞膚 ~ 觸憲鑰築糧觸觸衊壓獵) 更多
NCT02343627 (CTgov)	临床2期	甲癣	47	NVXT Solution (NVXT Solution)	淵鑰蓋鬱壓簾襯糧願夢(壓夢壓選鹽鹽鏇築鹹淵) = 淵膚齋選鹽蓋鹹積憲淵壓簾壓醖衊簾鹹鹽製鹽 (齋願鬱廠壓膚願蓋範糧, 襯鹹積網窪鬱遞膚顧願 ~ 鏇築糧繭窪衊餘願艱襯) 更多	-	2018-08-22
				Vehicle of test product (Vehicle of Test Product)	淵鑰蓋鬱壓簾襯糧願夢(壓夢壓選鹽鹽鏇築鹹淵) = 餘醖糧襯糧製鏇艱蓋夢壓簾壓醖衊簾鹹鹽製鹽 (齋願鬱廠壓膚願蓋範糧, 夢餘鑰蓋夢鬱簾築壓壓 ~ 網遞夢廠觸壓積餘窪構) 更多